NextGen Clinical Trial Investigator Training - Session 1, August 4
The NextGen Clinical Trial Investigator Training is a five-session educational program designed for faculty who are either involved in clinical trials or who would like to become involved. The series includes lectures and panel discussions from leaders across the University of Missouri System, as well as Washington University in St. Louis, to define the regulatory, operational and ethical components of clinical trials, with the goal of developing a skilled workforce that provides the highest level of patient safety, teamwork and data quality. The program also covers institution-specific resources for investigators.
Timeframe: Five weeks, starting Aug. 4 through Sept. 1, 4:30 to 7:30 p.m.
August 4 - Session 1: Good Clinical Practice & Team Science
August 11 - Session 2: What is a Clinical Trial?
August 18 - Session 3: Patient & Community Engagement & Responsible Conduct of Research
August 25 - Session 4: Research Funding & Team Management
September 1 - Session 5: Institutional Resources
|Welcome: Mary Hindle, Senior Director of Education – Health Affairs, Executive Vice Chancellor for Health Affairs Office, University of Missouri -Columbia|
|NextGen PH and ICTS – Rick Barohn, MD, Executive Vice Chancellor for Health Affairs, and Executive Director of NextGen Precision Health, University of Missouri-Columbia, and Bill Powderly, MD, Associate Dean for Clinical and Translational Sciences, Washington University in St. Louis.|
|Patient Perspective: Engaging with Patient Research Advocates –Kim Kimminau, PhD, Chief of Staff and Chief of Planning for the Executive Vice Chancellor for Health Affairs Office, University of Missouri-Columbia, and Jeff Ordway, Patient Advocate, University of Missouri-Columbia|
|What is a Clinical Trial – Parvesh Kumar, MD, Associate Dean of Clinical & Translational Research, University of Missouri-Columbia School of Medicine|
|Team Science – Fungai Chanetsa, PhD, MPH, Associate Director of Research Administration at Ellis Fischel Cancer Center, University of Missouri-Columbia|
|Good Clinical Practice – Laura Herbelin, Clinical Trial Expert Consultant, University of Missouri-Columbia|